These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38724504)

  • 1. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.
    Prabhu KS; Ahmad F; Kuttikrishnan S; Leo R; Ali TA; Izadi M; Mateo JM; Alam M; Ahmad A; Al-Shabeeb Akil AS; Bhat AA; Buddenkotte J; Pourkarimi E; Steinhoff M; Uddin S
    Cell Death Discov; 2024 May; 10(1):225. PubMed ID: 38724504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
    Ling YH; Liebes L; Zou Y; Perez-Soler R
    J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
    Yin L; Kufe T; Avigan D; Kufe D
    Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.
    Yin Y; Qi X; Qiao Y; Liu H; Yan Z; Li H; Liu Z
    Curr Cancer Drug Targets; 2019; 19(1):50-64. PubMed ID: 30289077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties.
    Shao R; Liu S; Liu W; Song C; Liu L; Zhu L; Peng F; Lu Y; Tang H
    MedComm (2020); 2024 May; 5(5):e562. PubMed ID: 38737470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.
    Ochoa TA; Rossi A; Woodle ES; Hildeman D; Allman D
    J Immunol; 2024 Jan; 212(1):154-164. PubMed ID: 37966267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells.
    Rossi UA; Finocchiaro LME; Glikin GC
    Anticancer Agents Med Chem; 2017; 17(5):754-761. PubMed ID: 27677689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
    Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
    Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
    Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
    Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
    Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
    Feng M; Wang J; Sun M; Li G; Li B; Zhang H
    Cancer Cell Int; 2021 May; 21(1):279. PubMed ID: 34039348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction.
    Rong J; Li P; Ge Y; Chen H; Wu J; Zhang R; Lao J; Lou D; Zhang Y
    Colloids Surf B Biointerfaces; 2020 Feb; 186():110674. PubMed ID: 31855686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
    Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
    Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNIP3 overexpression may promote myeloma cell apoptosis by enhancing sensitivity to bortezomib via the p38 MAPK pathway.
    Xiao P; Chen X; Dong Z; Fan W; Chen Y; Su J; Wang Q; Ma L
    Hematology; 2023 Dec; 28(1):2231739. PubMed ID: 37401850
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Rani S; Sahoo RK; Kumar V; Chaurasiya A; Kulkarni O; Mahale A; Katke S; Kuche K; Yadav V; Jain S; Nakhate KT; Ajazuddin ; Gupta U
    Mol Pharm; 2023 Jan; 20(1):524-544. PubMed ID: 36306447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
    Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
    Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
    Hattori K; Takano N; Kazama H; Moriya S; Miyake K; Hiramoto M; Tsukahara K; Miyazawa K
    Oncol Lett; 2021 Sep; 22(3):680. PubMed ID: 34345305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.